Neutralizing IL-1α using monoclonal antibodies, which almost completely depleted IL-1α in serum (Fig. 6a), led to a marked improvement of GVHD mortality and a significant reduction of GVHD pathological scores (Fig. 6b, c). Here, IL1A is linked to graft versus host disease.